الفهرس 
AbstractOnly 14 pages are availabe for public view
 |  | from | 128 |  |  |
| | | from | 128 | | |
Abstract
Toxicity of gold nanoparticles (GNPs) depends on their size, shape, dose, capping agent, surface chemistry, animal model used, frequency and duration of exposure, and route of administration. In the present study, we investigated the clinicopathological changes associated with administration of GNPs and anti-EGFR-GNPs in healthy and tumor-induced hamsters, respectively. Systemic repeated I/P injection of ≈18 nm naked GNPs (as verified by transmission electron microscope) at a dose of 30 ppb daily for 2 weeks induced macrocytosis, hypochromasia, leukocytosis, neutrophilia, mild lymphocytosis and monocytosis. Hepatic and renal function parameters remained unchanged in GNPs-treated hamsters when compared to control group. Histopathological examination of parenchymatous organs revealed variable lesions in liver and spleen which was correlated to results of gold distribution in tissues. Gold was present in high amounts in liver and spleen followed by kidney, lung and heart as measured by atomic absorption spectroscopy. Local injection of anti-EGFR-GNPs for 4 times was safer than systemic injection for 4 times in hamsters bearing squamous cell carcinoma in cheek pouch that was evident from clinicopathological and histopathological examinations of hamsters. Systemic injection of anti-EGFR-GNPs induced normocytic hypochrmic anemia, while the local injection induced normocytic normochromic anemia. Significant neutrophila and monocytosis were noticed in systemic anti-EGFR-GNPs hamsters when compared to the locally injected ones. The measured serum biochemical parameters remained unchanged in both systemic and local anti-EGFR-GNPs groups when compared to control hamsters. Histopathological examination revealed variable lesions in liver and kidney of systemic anti-EGFR-GNPs group, while tissues of local anti-EGFR-GNPs showed normal architecture. Tissue distribution results showed dramatic decrease in gold concentration in local anti-EGFR-GNPs group when compared to the systemic anti-EGFR-GNPs which had significant residues of gold in liver, spleen, kidney, lung and heart.